New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women
May 01 2024 - 12:00AM
Business Wire
A leading driver of maternal mortality and
morbidity, preeclampsia impacts 1 in 12 pregnancies
As May marks Preeclampsia Awareness Month, leading maternal
health experts, preeclampsia survivors and industry leaders have
come together on a new campaign, “Preeclampsia Prevention is
Possible.” The campaign elevates awareness of a major paradigm
shift underway focused on the prevention of the disease,
encouraging the use of evidence-based strategies so pregnant
patients and providers can actively work together to create the
healthiest pregnancy possible.
“Preeclampsia is often viewed as a complication with limited
ability to intervene early and lower the risk of developing the
condition,” said Eleni Tsigas, CEO of the Preeclampsia Foundation
and preeclampsia survivor. “However, all year long, and especially
during Preeclampsia Awareness Month, we’re amplifying the message
that we are in an era where we can better predict, prevent, and
prevail over the adverse outcomes caused by preeclampsia. Providers
have tools in the preeclampsia toolbox to work proactively with
their patients to prevent this serious pregnancy complication and
decrease its lifelong health effects.”
Impacting one in 12 pregnancies, preeclampsia can send a
seemingly normal pregnancy into a crisis in a matter of days or
even hours. Preeclampsia also takes a toll on moms and their
families across a lifetime:
- Survivors have an increased risk for stroke as well as kidney,
liver, and brain damage
- There is an increased risk of chronic hypertension,
cardiovascular disease, and blood clots
- It is a major cause of preterm birth
- And pregnancy complications like preeclampsia are linked to
long-term health impacts in children, including risk of obesity,
high blood pressure, high cholesterol or high blood sugar
“We must not accept that there’s nothing we can do to prevent
pregnancy complications like preeclampsia,” said Christopher
Robinson, MD, MSCR, FACOG, maternal-fetal medicine specialist at
Charleston Maternal Fetal Medicine. “When leveraged, these
strategies can create better outcomes for moms and their babies'
immediate and long-term health by preventing more cases of
preeclampsia.”
“Driven by technology to predict preeclampsia months in advance,
there will be a major shift from reactive to proactive care in how
we manage and hopefully prevent preeclampsia,” said Maneesh Jain,
CEO and co-founder of Mirvie, a company developing predictive tools
and support that drive preventive and personalized pregnancy care.
“With objective, personalized data, pregnant patients can finally
know their risk, create a plan and work with their care team to
take every possible measure to prevent preeclampsia.”
Patients and providers can access the educational toolkit at
PreeclampsiaPrevention.com. The toolkit offers pregnant patients as
well as those planning a pregnancy a discussion guide on what
should be addressed about preeclampsia when speaking with their
care teams and highlight evidence-based strategies that can be
incorporated into daily routines to prevent preeclampsia, including
taking baby aspirin; dietary, exercise, and sleep recommendations;
and monitoring blood pressure at-home.
ABOUT MIRVIE
Mirvie is delivering predictive tools and support that drive
preventive and personalized pregnancy care. One in five pregnancies
is impacted by complications that lead to lifelong health
consequences for expecting parents and babies. The proprietary
Mirvie RNA platform uses a simple blood test to reveal vital
information about a pregnancy’s unique biology and detect
complications months before they occur. The idea for Mirvie was
sparked by the personal experience of one of the founders whose
daughter was born prematurely. Mirvie’s team of world-class
scientists and entrepreneurs have brought to market category-first,
non invasive tests in both women’s health and in early cancer
detection, used by millions today. Founded in 2018, Mirvie has
raised more than $90 million in early-stage financing from top-tier
investors, including Decheng Capital, Foresite Capital, General
Catalyst, GV, Khosla Ventures, and Mayfield. Mirvie is based in
South San Francisco, California. To learn more about Mirvie, please
visit www.mirvie.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430574759/en/
Kate Enos kate@mirvie.com